Popular Searches:
Recommended Posts
Search Results
Ampersand Capital Partners, a Boston-based middle-market private equity firm dedicated to growth-oriented investments in healthcare and life sciences, has announced the closing of its latest fund, Ampersand 2026 (“AMP-26”) Limited Partnership, with $1.5 billion in limited partner commitments. The closing was announced on May 28, 2026. AMP-26 is Ampersand’s twelfth primary fund since 1992 and held a single close at the hard cap in less than five months from launch — a strong signal of institutional demand for the firm’s specialised healthcare investment strategy.
AMP-26 received strong support from a diversified and global set of institutional investors including endowments, foundations, pension plans, insurance companies, funds of funds and family offices. The oversubscribed close and compressed timeline reflect the depth of conviction among both existing and new LPs in Ampersand’s focused approach to healthcare and life sciences investing.
Herb Hooper, Managing Partner at Ampersand, expressed gratitude for the exceptional support from both existing and new investors and for their continued confidence in the firm’s specialised investment strategy. He described the strategy’s core as partnering with founders and management teams to build market-leading companies that provide mission-critical tools and services to the innovation ecosystem within healthcare and life sciences.
Ampersand was founded in 1988 and has spent more than three decades as a trusted partner to founders and CEOs, helping accelerate growth and build market-leading companies across its core healthcare sectors. With this new fund, Ampersand intends to continue the firm’s strategy of partnering with great entrepreneurs within our core sectors through both majority and minority investments in companies with $10 to $200 million in revenue and positive EBITDA.
The firm’s healthcare focus spans five core investment areas: laboratory products, laboratory services, contract manufacturing, pharma services, and specialty products — a sector-specialist framework that has produced a portfolio including companies such as Adaptas, Alcami, Brammer Bio, GENEWIZ, Nexelis, and Tjoapack.
With over $4 billion of assets under management and offices in Boston, Amsterdam, and London, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. The firm’s three-continent operating presence gives it direct access to the European and North American healthcare ecosystems — a meaningful competitive advantage in a sector increasingly shaped by transatlantic innovation and regulatory dynamics.
McDermott Will & Schulte LLP provided legal services to Ampersand for the fundraise.
The AMP-26 closing positions Ampersand to continue its disciplined, sector-specialist investment approach at a moment of significant structural opportunity in healthcare and life sciences. With AI, diagnostics innovation, and pharmaceutical services all experiencing rapid transformation, Ampersand’s 35-year track record of backing mission-critical healthcare businesses is well-aligned with the next wave of innovation the sector will demand.
Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with over $4 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, Amsterdam, and London, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. The firm has helped build numerous market-leading companies across each of its core healthcare sectors since its founding over 35 years ago.
